Researchers have identified a pivotal protein, glycoprotein nonmetastatic melanoma B (GPNMB), that facilitates the spread of Parkinson's-related damage across brain cells. Targeting this protein may pave the way for innovative strategies aimed at decelerating the progression of this neurodegenerative condition.
Lead researcher Dr. Alice Chen-Plotkin, Parker Family Professor of Neurology, emphasized the significance of these findings: "Many patients are diagnosed in the early stages of Parkinson's, where symptoms are manageable, yet no current treatment effectively slows the disease's advancement. These initial results are a promising step towards developing such therapies."
Understanding the Spread of Parkinson's Disease
Parkinson's disease affects over one million Americans, with approximately 90,000 new diagnoses each year. While the precise causes remain elusive, it is well-established that the disease progresses through the brain in distinct stages.
Central to this process is the protein alpha-synuclein, which forms abnormal aggregates within neurons. These aggregates not only harm the affected cells but also transfer to neighboring healthy neurons, perpetuating the spread of the disease.
As more brain regions are impacted, patients may experience worsening symptoms, including tremors, mobility issues, and challenges with balance and swallowing.
Current therapeutic approaches, such as levodopa and deep-brain stimulation, can alleviate symptoms but do not address the underlying progression of Parkinson's disease.
Microglia and GPNMB: A Self-Reinforcing Cycle
In previous studies, Dr. Chen-Plotkin and her team pinpointed GPNMB as a crucial molecule in the transmission of alpha-synuclein between neurons, marking it as a potential target for future treatments. Their latest research reveals that microglia, the brain's immune cells, significantly contribute to GPNMB production in Parkinson's disease. When neurons sustain damage, nearby microglia produce increased amounts of this protein.
Enzymatic processes then release parts of GPNMB from the cell surface, facilitating its movement between brain cells. In preclinical laboratory experiments, researchers engineered antibodies that effectively blocked GPNMB, preventing the pathological spread of alpha-synuclein.
Dr. Chen-Plotkin noted, "Our findings suggest that Parkinson's disease may be driven by a self-reinforcing cycle: as alpha-synuclein accumulates, it damages neurons, prompting GPNMB release, which in turn accelerates the spread of alpha-synuclein and further neuronal damage. Interrupting this cycle could slow or even halt the progression of the disease."
Human Brain Analysis Confirms Findings
To validate their results, the research team analyzed tissue samples from 1,675 brains stored in the Penn Brain Bank. They discovered that individuals with genetic variants linked to higher GPNMB production exhibited more extensive alpha-synuclein pathology, reinforcing the protein's crucial role in the disease's progression.
Importantly, elevated GPNMB levels were not associated with markers for other neurodegenerative diseases, such as Alzheimer's. Dr. Chen-Plotkin concluded, "While these results are promising for laboratory models and human brain tissue analysis, further work is essential to translate this therapy into clinical applications. Nonetheless, we remain optimistic about developing novel treatments for Parkinson's disease."
This research received support from the National Institutes of Health and various funding bodies.
